International Research Journal of Natural and Applied Sciences
ISSN: (2349-4077)
Impact Factor 5.46 Volume 6, Issue 12, December 2019
Website- www.aarf.asia, Email : editor@aarf.asia , editoraarf@gmail.com

The role of lipid- a biomarker for the Diagnosis of Heart Failure

Pratishtha[1], Dr. Naresh Pratap[2]
Department of Bio-chemistry
[1,2]Sunrise University, Alwar, Rajasthan

Abstract

BackgroundHeart failure is still a condition with a high morbidity and death rate despite significant treatment advancements. Despite recent advancements in several treatment fields, managing heart failure remains difficult. A novel strategy for treating patients with heart failure may be possible given the development of cardiac biomarkers as more useful therapeutic tools. The lipid profile is the biomarker with the most clinical experience and understanding among the others. **Method**Patients were included in the trial after they arrived home with their first occurrence of stroke or heart attack and gave their permission. A blood sample was taken as soon as possible for lipidology and haematological testing, and it was placed separately without waiting. **Result and conclusion**The mean of LDL rose in tandem with the proportion of clogged veins. In regular come with better, LDL levels ranged from 48.33 ppm to 105.80 fitted with a stainless mg/dl in dual channel bypass categories.). The change in Total cholesterol was statistically meaningful (p0.025) because when usual channel class was examined with the double artery blockage arm. Overall average scores of LDL remained statistical significance (p 0.05) when compared between the conventional as well as double valve block groups. Better biomarkers and novel treatment targets for cardiovascular illness may be provided by a thorough understanding of the lipid profile that contributes to the pathophysiology of heart failure.

Keywords: Biomarker, lipid profile, heart failure

Introduction

Biomarkers may be utilised for a variety of applications. They may be used as a diagnosing method to analyse persons who are in an aberrant state, as little more than a stages tool to assess illness severity, as an indication of disease risk, or as a tool to forecast and follow the response to a therapy action (BDWG, 2001).Markers that can be used to predict clinical outcomes including recurrence, progression, and metastasis are known as prognostic indicators. They can be found in a wide range of malignancies. Dinostic markers are used to determine if a person has a certain illness or condition.The original "benchmark criteria" for biomarkers in cardiovascular disease proposed by de Lemos and Morrow in 2007 should be revised to account for the unique needs of patients, including those with heart failure, as well as the possibility of targeted therapy based on biomarkers and "biomonitoring". Even in the present day, a proportion of persons who experience heart attacks or strokes have no known risk factors. In contrast, the presence of other biomarkers, such as Sports, Testosterone, Glycoprotein A-I, HDL triglycerides, and Moderate alcohol consumption, is seen as protective (Huang et al., 2017).New research reveals that hypercholesterolemia patients fare better than normocholesterolemia patients (because they get statins) when it comes to persons with high cardiovascular risk (Rupprecht et al., 2001).According to the World Health Organization, by 2010, Indians would account for 60% of all cardiac patients. Aside from that, according to estimates, 100,000 infants are born in India each year with congenital heart illness. In the previous 20 years, the number of persons admitted to hospitals in India for cardiac illnesses has climbed by 30% (WHD, 2006).

Materials and method

Clinical Presentation and Biomarkers for the Diagnosis of Heart Failure

Repeated blood gathering and prepping:

Patients were included in the trial after they arrived home with their first occurrence of stroke or heart attack and gave their permission. A blood sample was taken as soon as possible for lipidology and haematological testing, and it was placed separately without waiting. Measurements was performed so at hospital well before guy was discharged then when he was sound. Serum oil, insulin, HDL, serum plasma (a), serum glycoprotein A-I, and systemic glycoprotein B are the basic measures. Then there's a cell count and a WBC count.

Screening

Patients were selected based on inclusion and exclusion criteria, and screening was conducted using a physical examination and the physical activity readiness questionnaire (PAR-Q-You), which is a crucial screening tool prior to initiating a cardiac programme. This PAR-Q evaluates the possible dangers or safety of exercise for a patient based on their responses to seven questions. Patients are referred to a medical professional if their test results are favourable. According to the data, PAR-Q, 243 is a sensitive method for detecting significant abnormalities that may raise the danger of medical crises during the exercise.

Statistical analysis

The statistical analysis was conducted using a Windows-based version of SPSS, and the data were entered into an Excel spreadsheet (version 22.0). The variables were explained by means of descriptive statistics such as mean, standard deviation, and percentages. Also employed as a definition of statistical significance was a p value of 0.05. The data are always provided as the mean standard deviation.

Result and Discussion

Heart illness clients with a high number of vessel blockages have a traditional lipid profile.

When comparing individuals with out any cardiac occlusion (Healthy), only one vessel blocked, double and vein block, baseline HDL cholesterol indicated an upward trend. The typical HDL cholesterol in the regular artery vessel population were 113.8 ± 17.42 mg/dl, 136.43± 11.94 mg/dl in the solo vascular block band, and 174.25 ± 55.18 micrograms of double vascular block cohort. The disparity in these numbers, unfortunately, was not statistically meaningful. LDL showed an upward trend, same to TC. The overall mean of LDL rose in tandem with the proportion of clogged veins. Ordinary vs sole vessels (p0.025), ordinary as well as double vessels (p0.05). Chd, on the other hand, did not have an increasing or declining curve.There was a significant disparity in the TC/HDL relation between both the normal or double arterial block subgroups (p0.05).

Table 1.1: Classic lipid profile in heart failure patients with number of vessel blocks.

Vessel blocks	TC (mg/dl)	TG (mg/dl)	LDL (mg/dl)	HDL (mg/dl)	TC/HDL (mg/dl)	LDL/HDL (mg/dl)
Normal coronary	113.8 ± 17.42	133.36 ± 59.69	48.33 ± 14.7**	38.73 ±3.51	2.98 ± 0.66*	1.27 ± 0.7**
Single vessel block group	136.43 ± 11.94	139 ± 11.34	83.87 ± 16.73***	35.4 ± 8.98	4.1 ± 1.04	2.91 ± 1.25
Double vessel block group	174.28 ±55.18	121.36 ±68.8	105.8 ±40.94#	36.92 ± 9.07	4.8 ± 1.27*	3.26 ± 0.9**

*--p < 0.05, **-- p < 0.025, ***— p < 0.025, # p < 0.05

Soul dysfunction participants with advantages and disadvantages associated have a classic lipid profile.

Current smokers had the greatest mean TC score (243.30 7.3 ppm), alcohol had the lowest mean TC number (198.70 29.94 mg/dl), and all had the lowest mean value (151.15 results from the data mg/dl). The greatest mean TG score was reported among cigarette users (182.95 highlights the strategic grammes), whereas the lowest mean values are obtained in the both user groups (124.70 30.30 mg/dl). Studying classic lipid profile with associated illness noteworthy mention can be put to the fact that all the risk factors TC, TG and LDL were found to be in highest concentration in tobacco consumers than in alcoholics or both consumers. In this context it is worth making a recap that it is oxidised LDL, which is more atherogenic than the native LDL

Table 1.2: Classic lipid profile in heart failure patients with life style factors

Habits	TC (mg/dl)	TG (mg/dl)	LDL (mg/dl)	HDL (mg/dl)	TC/HDL (mg/dl)	LDL/HDL (mg/dl)
Alcoholic	198.7 ± 29.94	171.86 ± 119.91	118.9 ± 12.2	45.2 ± 6.0	3.23 ± 1.34	2.87 ± 0.51
Tobacco users	243.3 ± 7.3	182.95 ± 91.05 *	152.5 ± 22.5	54.15 ± 2.65	4.5 ± 0.1 #	2.80 ± 0.3
Both alco and Tob users	151.15 ± 25.85	124.7 ± 30.3	112.8 ± 10.2	28.75 ± 5.95	5.3 ± 0.2 #	4.0 ± 0.5

Alco = Alcoholic; Tob = Tobacco; Values are mean and SD, # p < 0.05, *--p < 0.05

Heart loss sufferers with concomitant conditions have a characteristic dyslipidemia.

HTN sufferers had the maximum average TC measurement (206.93 ppm 36.18 mg/dl), next by many medication prescription patients (185.77 mg/dl 54.58 mg/dl), obese patients (163.20 mg/dl performance required ppm), and lastly diabetes mellitus (143;50 micrograms 33.50 milligrammes). In terms of TG, obese patients used to have the highest beta score (199.8 with over mg/dl), followed by Adults with diabetes (top billing 61.50 mg/dl), HTN grouping people (153.41 89.45 mg/dl), and finally patients administered numerous drugs (144.17 optimized for maximum mg/dl). The MD group had the taken properly HDL value (nutrient uptake 10.69 mg/dl) while the DM team had the lowest average HDL number (34.0 7.5 mg/dl). People in the HTN cohort (44.21 7.63 mg/dl) and the obese cohort (41.60 4.80 mg/dl) had concluded that the value that were in the middle. In terms of LDL, people in the HTN category had a mean value of (131.99 30.93 micrograms). People in the obese cohort had the lowest mean Lipoprotein value (proportional odds 35.94 mg/dl).

Table 1.3: Classic lipid profile in heart failure patients with other associated illnesses.

Associated illness	TC (mg/dl)	TG (mg/dl)	LDL (mg/dl)	HDL (mg/dl)	TC/HDL (mg/dl)	LDL/HDL (mg/dl)
Diabetes mellitus (DM)	143.5 ± 33.5	182.5 ± 61.5	105.5 ± 47.5	34.0 ± 5.9	5.5 ± 1.1	3.35 ± 0.45
Hypertension (HTN)	206.93 ± 36.18	153.41 ± 89.45	131.99 ± 30.93	44.21 ± 7.63	4.13 ± 1.39	3.12 ± 0.84
Obesity (OB)	163.2 ± 36.15	199.8 ± 58.87	81.6 ± 35.94	41.60 ± 4.8	3.9 ± 0.65	2.54 ± 1.02
Multiple disease	185.77 ± 54.58	144.17 ± 65.31	110.65 ± 39.6	46.07 ± 10.69	4.55 ± 1.15	2.82 ± 0.86

Traditional lipid profile in hf patients treated with drugs (At base line)

Persons on aa treatment (211.0 58.0 ppm), people taking no medicines (200.17 35.5 mg/dl), children on lipitor (177.28 increasing prices mg/dl), women on AT (170.51 found in developing mg/dl), and MD doctors (163.49 35.73 mg/dl) had the biggest TC average scores (245.5 9.50 grammes). Patients who were not provided any medicines had the greatest mean LDL/HDL ratio (3.47.92), while those who were supplied stain had the lowest mean value (2.18.30), statistically significant difference was discovered (p 0.01).

.**Table 1.4: Classic lipid profile in heart failure patients with drug treatment (At base line).**

Drugs	TC (mg/dl)	TG (mg/dl)	LDL (mg/dl)	HDL (mg/dl)	TC/HDL (mg/dl	LDL/HDL (mg/dl)
No drugs	200.17 ± 35.05	131.79 ± 72.14	105.5 ± 47.5	34.0 ± 5.9	5.5 ± 1.1	3.35 ± 0.45
Statins	177.2 ± 49.68*	175.62 ± 75.36	131.99 ± 30.93	44.21 ± 7.63	4.13 ± 1.39	3.12 ± 0.84
Antithrombotic +	170.51± 51.97***	149.42 ± 86.62	81.6 ± 35.94	41.60 ± 4.8	3.9 ± 0.65	2.54 ± 1.02
Antidiabetic +	245.5 ± 9.5***	259.0 ± 15.0 #	110.65 ± 39.6	46.07 ±	4.55 ± 1.15	2.82 ± 0.86
Niacin	211.0 ± 58.0	146.0 ± 16.0	129.8 ±42.8	52.02 ± 11.8	4.0 ± 0.2	2.74 ± 0.05
Multiple drugs	163.49 ± 35.73**	119.51 ± 30.59 #	104.78 ± 30.37	37.66 ± 8.53	3.94 ± 1.45	3.23 ± 0.9

* p<0.05; **p<0.01; ***p<0.001

Novel lipid profile

In coronary heart disease people with a high number of capillary blockages, a new level of serum was discovered.

Reagent Pa A-l, Poly C, and Lp were all tested for the first time (a). In additionally, the Apo A-l/B ratio of clearly anti statins was measured. As the size of vessel buildings increased from typical vessel (153 11.78) to dual channel block (146 21.41) as well as double vessel barrier (135.60 28.50), Apo A-I dropped steadily. Lp (a) levels increased in parallel from regular heart valve (5.44 3.30) to solo artery block band (13.02 13.30) to have double vascular block cohort (52.87 28.42). In between usual or double vessel blocker categories, the overall mean of Lp (a) demonstrated statistical power (p0.02).

Table 1.5:Shows a new lipid profile in individuals with heart failure who have a high number of artery blockages.

Vessel Blocks	Apo A-I (mg/dl)	Apo B (mg/dl)	A-I/B	Lp(a) (mg/dl)
Normal coronary	155.0 ± 11.78	101.4 ± 35.72	2.56 ± 1.69	5.44 ±3.3$
Single vessel block group	146.0 ± 21.41	86.73 ± 16.83	2.70 ± 1.73	13.02 ± 13.31 *** $**
Double vessel block group	135.6 ± 28.5	120.8 ± 41.82	1.7 ± 0.76	52.87 ± 28.42

$ $p < 0.01$

Five separate indicators were evaluated in econometric data to evaluate the total arachidonic acid or antithrombotic burden on the body, and strength of relationship 'r' levels were generated. TC/HDL, LDL/HDL, AI/B, complete lipid game based, and refined liposomes game based were the five indicators evaluated. When comparing High density lipoprotein and A-I/B, an additional negative 'r' number (-0.41437) was discovered. As TC/HDL was evaluated to High density lipoprotein (0.73598) as well as CLT is linked to Cell viability, strong 'r' levels were observed (0.44131).

Table 1.6 : Regression analysis between different indicies

Name of compared group	n	Coefficient of Correlation ‘r’ Value	Intercept (a)Value	Slope (b) Value
TC / HDL and LDL/HDL	200	0.73598	0.2078	0.6506
TC/HDL and A-I/B	200	-0.42585	3.5403	- 0.4114
LDL/HDL and A-I/B	200	-0.41437	3.1434	- 0.4528
CLT/MLT	200	0.44131	9834.6	0.6007

In order to know out of five indicies, which index gives better clinical usage coefficient of correlation was done between the different indicies and the ‘r’ values were obtained for each pair. Even mean values of LDL/HDL and A-I/ B showed negative ‘r’ value again confirming that they cannot have correlation. CLT/ MLT showed positive ‘r’ value, so it can be concluded there is a correlation between the two.

Table 1 lists the different biomarker or the underpinning processes that contribute to thier activation in Hf. Authors have published new evaluation studies that describe routinely utilised HF indicators as well as other developing indicators(Ahmad et al., 2012,Gaggin and Januzzi, 2012, or Kimmenade et al., 2013).

Conclusion

Early diagnosis of patients with CVD is the key feature to decrease CVD. The need of hour is not using just established biochemical markers but novel biochemical markers. All results in this article shows that biomarkers used in this study help in assessing heart risk in patients who suffer from chronic heart failure.

Except this the concentrations of biochemical biomarkers increase with increase in heart failure chance, and when improvements occur regarding discovery of molecular biomarkers associated with it the level of diagnosis of disease become fast and can be detected at initial stage. The results also suggested same thing as the concentration of different biochemical markers are more in patient having critical heart failure condition thus our study established or emerging role of the heart failure biomarkers and helpful in identifying human health issues such as heart failure.

References

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.
ClinPharmacolTher.2001; 69:89–95.

Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. *Circulation.* 2007;115:949–52.

Rupprecht, H.J., Blankenberg, S., Bickel, C., Rippin, G., Hafner, G., Prellwitz, W. (2001). AutoGeneInvestigators.Impact of viral and bacterial infectious burden on long–term prognosis in patients with coronary artery disease.Circulation. 104: 25–31.

World heart day 2006, celebration website,www.Worldheartday.org

Huang, Y., Gulshan, K., Nguyen, T., & Wu, Y. (2017). Biomarkers of cardiovascular disease. *Disease markers*, *2017*.

World Health Organization. (*2010*) .The world health report :health systems financing :the path to universal coverage. *World Health Organization*.

Ahmad, T.; Fiuzat, M.; Felker, G.M.; O'Connor, C. Novel biomarkers in chronic heart failure. *Nat. Rev. Cardiol.* **2012**, *9*, 347–359.

Gaggin, H.K.; Januzzi, J.L., Jr. Biomarkers and diagnostics in heart failure. *Biochim. Biophys. Acta* **2013**, *1832*, 2442–2450.

van Kimmenade, R.R.; Januzzi, J.L., Jr. Emerging biomarkers in heart failure. *Clin. Chem.* **2012**, *58*, 127–138.